[1] Griswold, M. G., Fullman, N., Hawley, C., Arian, N., Zimsen, S. R., Tymeson, H. D., ... & Farioli, A. (2018). Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet, 392(10152), 1015-1035.
[2] Assiri, M. A., Ali, H. R., Marentette, J. O., Yun, Y., Liu, J., Hirschey, M. D., ... & Fritz, K. S. (2019). Investigating RNA expression profiles altered by nicotinamide mononucleotide therapy in a chronic model of alcoholic liver disease. Human genomics, 13(1), 1-13.
[3] Zong, Z., Liu, J., Wang, N., Yang, C., Wang, Q., Zhang, W., ... & Deng, H. (2021). Nicotinamide mononucleotide inhibits hepatic stellate cell activation to prevent liver fibrosis via promoting PGE2 degradation. Free Radical Biology and Medicine, 162, 571-581.
[4] Luo, C., Ding, W., Zhu, S., Chen, Y., Liu, X., & Deng, H. (2022). Nicotinamide Mononucleotide Administration Amends Protein Acetylome of Aged Mouse Liver. Cells, 11(10), 1654.
[5] Luo, C., Ding, W., Yang, C., Zhang, W., Liu, X., & Deng, H. (2022). Nicotinamide Mononucleotide Administration Restores Redox Homeostasis via the Sirt3–Nrf2 Axis and Protects Aged Mice from Oxidative Stress-Induced Liver Injury. Journal of Proteome Research.
共有 0 条评论